J. B. Chemicals & Pharmaceuticals Limited (BOM:506943)
1,892.70
-12.05 (-0.63%)
At close: Feb 13, 2026
BOM:506943 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 41,930 | 39,180 | 34,842 | 31,493 | 24,242 | 20,425 | |
Revenue Growth (YoY) | 9.47% | 12.45% | 10.63% | 29.91% | 18.69% | 15.09% |
Cost of Revenue | 13,816 | 13,545 | 12,142 | 11,963 | 8,655 | 7,227 |
Gross Profit | 28,115 | 25,635 | 22,700 | 19,530 | 15,588 | 13,198 |
Selling, General & Admin | 9,804 | 9,172 | 8,111 | 7,278 | 5,662 | 4,258 |
Other Operating Expenses | 6,991 | 6,153 | 5,661 | 5,190 | 4,460 | 3,358 |
Operating Expenses | 18,584 | 17,035 | 15,156 | 13,612 | 10,849 | 8,303 |
Operating Income | 9,530 | 8,600 | 7,544 | 5,918 | 4,739 | 4,895 |
Interest Expense | -47.05 | -106.45 | -436.52 | -347.68 | -40.85 | -67.43 |
Interest & Investment Income | 53.31 | 53.31 | 44.26 | 25.39 | 9.39 | 17.79 |
Currency Exchange Gain (Loss) | 7.18 | 7.18 | 44.07 | -110.87 | -38.01 | 42.34 |
Other Non Operating Income (Expenses) | 238.58 | -4.72 | -5.79 | -2.79 | 1.06 | 50.88 |
EBT Excluding Unusual Items | 9,783 | 8,550 | 7,190 | 5,482 | 4,671 | 4,939 |
Gain (Loss) on Sale of Investments | 322.08 | 322.08 | 327.43 | 69 | 350.43 | 505.5 |
Gain (Loss) on Sale of Assets | 2.12 | 2.12 | -2.32 | 0.07 | 24.05 | 524.37 |
Other Unusual Items | - | - | - | 1.28 | 3.98 | - |
Pretax Income | 10,107 | 8,874 | 7,515 | 5,552 | 5,049 | 5,969 |
Income Tax Expense | 2,569 | 2,278 | 1,989 | 1,452 | 1,189 | 1,484 |
Earnings From Continuing Operations | 7,538 | 6,596 | 5,526 | 4,100 | 3,860 | 4,485 |
Minority Interest in Earnings | - | - | - | -1.7 | -6.82 | -5.59 |
Net Income | 7,538 | 6,596 | 5,526 | 4,098 | 3,854 | 4,480 |
Net Income to Common | 7,538 | 6,596 | 5,526 | 4,098 | 3,854 | 4,480 |
Net Income Growth | 17.77% | 19.35% | 34.84% | 6.35% | -13.98% | 64.66% |
Shares Outstanding (Basic) | 156 | 155 | 155 | 155 | 155 | 155 |
Shares Outstanding (Diluted) | 159 | 159 | 159 | 157 | 155 | 155 |
Shares Change (YoY) | -0.27% | 0.07% | 1.26% | 1.23% | 0.10% | -2.86% |
EPS (Basic) | 48.29 | 42.45 | 35.66 | 26.50 | 24.93 | 28.98 |
EPS (Diluted) | 47.47 | 41.56 | 34.85 | 26.17 | 24.91 | 28.98 |
EPS Growth | 18.07% | 19.25% | 33.17% | 5.06% | -14.04% | 69.50% |
Free Cash Flow | - | 8,049 | 6,737 | 5,562 | 1,073 | 2,670 |
Free Cash Flow Per Share | - | 50.72 | 42.48 | 35.51 | 6.93 | 17.27 |
Dividend Per Share | 19.700 | 15.500 | 12.250 | 8.875 | 8.250 | 8.250 |
Dividend Growth | 29.18% | 26.53% | 38.03% | 7.58% | - | 50.00% |
Gross Margin | 67.05% | 65.43% | 65.15% | 62.01% | 64.30% | 64.62% |
Operating Margin | 22.73% | 21.95% | 21.65% | 18.79% | 19.55% | 23.97% |
Profit Margin | 17.98% | 16.84% | 15.86% | 13.01% | 15.90% | 21.93% |
Free Cash Flow Margin | - | 20.54% | 19.34% | 17.66% | 4.42% | 13.07% |
EBITDA | 11,357 | 10,188 | 8,813 | 7,038 | 5,384 | 5,498 |
EBITDA Margin | 27.09% | 26.00% | 25.30% | 22.35% | 22.21% | 26.92% |
D&A For EBITDA | 1,827 | 1,588 | 1,269 | 1,120 | 645.45 | 602.84 |
EBIT | 9,530 | 8,600 | 7,544 | 5,918 | 4,739 | 4,895 |
EBIT Margin | 22.73% | 21.95% | 21.65% | 18.79% | 19.55% | 23.97% |
Effective Tax Rate | 25.42% | 25.67% | 26.46% | 26.16% | 23.54% | 24.86% |
Revenue as Reported | 42,557 | 39,563 | 35,214 | 31,592 | 24,635 | 21,549 |
Advertising Expenses | - | 2,273 | 2,077 | 1,808 | 1,250 | 838.21 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.